REG - Abingdon Health PLC - Trading update

Abingdon HealthAnnouncement

Tue 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250805:nRSE9298Ta&default-theme=true

RNS Number : 9298T  Abingdon Health PLC  05 August 2025

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Regulation (EU) No 596/2014 which is part of UK law by
virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the
publication of this announcement via a Regulatory Information Service, this
inside information is now considered to be in the public domain.

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Trading update

 

Revenue for FY25 in line with market expectations of £8.6m

Continued strong revenue growth anticipated in FY26

 

York, U.K.  5 August 2025: Abingdon Health plc (AIM: ABDX), a leading
international developer, manufacturer and regulatory services provider for
rapid tests and med-tech, provides a trading update for the financial year
ended 30 June 2025 ("FY25").

 

Commercial and Operational Highlights

·    Continued growth of contract development and manufacturing
organisation ("CDMO") activities with several large contracts secured during
FY25 and post period-end including:

o  Contract win
(https://www.londonstockexchange.com/news-article/ABDX/contract-win-sexually-transmitted-disease-tests/16814507)
 for US$2m for development of sexually transmitted disease tests running
across 2025 and into 2026.

o  Funding award of £800,000 via UK Research and Innovation alongside a
distinguished group of partners to develop point-of-care rapid diagnostic
tests for malaria
(https://www.londonstockexchange.com/news-article/ABDX/funding-award-to-develop-test-for-malaria-parasite/16869616)
.

o  Strategic partnership
(https://www.londonstockexchange.com/news-article/ABDX/avian-flu-h5n1-lateral-flow-test/17063489)
s
(https://polaris.brighterir.com/public/abingdon_health/news/rns/story/x42j1or)
with Okos Diagnostics to jointly develop and commercialise avian flu (H5N1)
lateral flow kits for bovine health and human applications.

o  €2m CDMO contract win
(https://www.londonstockexchange.com/news-article/ABDX/eu2m-contract-win-for-companion-diagnostic-test/17081832)
for companion diagnostic test covering development, scale-up, technical
transfer, manufacture and full regulatory approval support with a European
biotech company.

o  Additional CDMO contract win
(https://www.londonstockexchange.com/news-article/ABDX/c-us-2-5m-companion-diagnostic-test-contract-win/17160388)
for development and regulatory approval of a companion diagnostic lateral flow
point of care test, with a global pharmaceutical company expected to generate
c. US$2.5m revenue over a 24-month period.

·    Expansion of integrated CDMO service offering with:

o  Acquisition
(https://www.londonstockexchange.com/news-article/ABDX/proposed-acquisition-and-placing-notice-of-gm/16584839)
 of regulatory service provider Compliance Solutions (Life Sciences)
in August 2024 for a maximum consideration of up to £3.2 million in cash
and shares.

o  Opening
(https://polaris.brighterir.com/public/abingdon_health/news/rns/story/xjzdygr)
of Abingdon Analytical Ltd, analytical services and performance evaluation
laboratory, in existing premises in Doncaster in December 2024.

·    Integration of CS Lifesciences well underway and contract
wins, including one for >£500k
(https://www.londonstockexchange.com/news-article/ABDX/cs-lifesciences-ltd-contract-win/16842040)
which has since been extended, underpinning significant growth potential in
FY26 and beyond.

·    Opening of US CDMO service site
(https://www.londonstockexchange.com/news-article/ABDX/opening-of-us-commercial-office-and-laboratory/16714258)
, including a commercial office and laboratories, in Madison, Wisconsin,
which was fully operational by April 2025.

 

Financial Highlights and Outlook

·    Revenue for FY25 expected to be in line with market expectations
of £8.6m (FY24: £6.1m).

·    Cash at bank and in hand of £1.9m (31 December 2024: £3.7m; 30
June 2024: £1.4m).

·    Recent acquisitions (IVDeology and CS Lifesciences) trading in line
with management expectations.

·    Investments made in new ventures (Abingdon Analytical Ltd and
Abingdon Health USA Inc.) supporting new contract wins.

·    The Board is confident of continued strong revenue growth based on
the above contract successes and continues to target a cash-flow positive
position in calendar year 2026.

The financial update above is provided subject to finalisation of the Group's
results for FY25 which are expected to be published in October 2025. Notice of
results will be provided in due course.

 

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented: "We are
pleased to announce in-line revenues are expected for FY25 and confirm that
initial progress in FY26 gives us confidence of continued strong revenue
growth. The investments and acquisitions the Company made during FY25 have
significantly strengthened our full service offering. We are now able to offer
a fully comprehensive CDMO service with the increasing importance of a
regulatory and performance evaluation skill set in addition to our research
and development, scale up and manufacturing expertise. This resonates well
with our current and prospective clients as evidenced by recent contract
wins."

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                            Via Walbrook PR
 Tom Hayes, CFO

 Zeus (Sole Broker and Nominated Adviser)                                    Tel: +44 (0)20 3829 5000
 Antonio Bossi / Jacob Walker (Corporate Finance)
 Fraser Marshall (Corporate Broking)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health plc

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
expertise offers lateral flow product development, regulatory support,
technology transfer and manufacturing services for customers looking to
develop new assays or transfer existing laboratory-based assays to a lateral
flow format.  Abingdon Health has the internal capabilities to take lateral
flow projects, in areas such as infectious disease and clinical testing,
including companion diagnostics, animal health and environmental testing, from
initial concept through to routine manufacturing; from "idea to commercial
success".  Abingdon Analytical Ltd offers performance evaluation for lateral
flow and other in vitro diagnostic assays from its Doncaster laboratory.

 

Abingdon's regulatory services companies, Compliance Solutions (Life
Sciences)
(https://urldefense.proofpoint.com/v2/url?u=https-3A__cslifesciences.com&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=PvbE1xuJgNrAaK0I9QSrYjO3acai4ITHsbheoH-Cavc&e=)
 and IVDeology
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.ivdeology.co.uk&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=mbRruUP_NEre93fFYpNkBweGVcmSCnXpjUyMQmUx1yI&e=)
, provide a broad range of regulatory services to the in vitro diagnostic and
wider medical device industry, to support customers in bringing products to
market across a range of territories including the USA, EU and the UK. Our
consultancy services range from design, implementation and maintenance of
quality management systems, preparation of technical files for regulatory
approvals, part-time and interim management support, auditing both internal
and external, management reviews and presentations, training and mentoring.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochure
(https://www.abingdonhealth.com/wp-content/uploads/2025/06/Abingdon-Health-Group-Leaflet-JUN2025.pdf)
 outlines the comprehensive support the Group can now provide to its
international customers.  For more information visit: www.abingdonhealth.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.abingdonhealth.com_&d=DwMFAg&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=b40MoFA_Q_fdsT77LXB5t3JFUZjlmpd2MVbmgvoBIOo&m=5rmPWmSeAYNtvo-wVGL_4V7p0wZ2qRPhbqDj6E6FHnhVakMVyzvk7wZG1jS6vI4P&s=Cd1Yy0EoU5vx33xedoTE3bCKbljgDOIRD8ol-bb59BM&e=)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTSSDESLEISEEA